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Aims An anti-angiogenic cleaved prolactin fragment is considered causal for peripartum cardiomyopathy (PPCM). Experimental
and first clinical observations suggested beneficial effects of the prolactin release inhibitor bromocriptine in PPCM.
...................................................................................................................................................................................................
Methods
and results
In this multicentre trial, 63 PPCM patients with left ventricular ejection fraction (LVEF) <_35% were randomly assigned to
short-term (1W: bromocriptine, 2.5 mg, 7 days) or long-term bromocriptine treatment (8W: 5 mg for 2 weeks followed
by 2.5 mg for 6 weeks) in addition to standard heart failure therapy. Primary end point was LVEF change (delta) from base-
line to 6 months assessed by magnetic resonance imaging. Bromocriptine was well tolerated. Left ventricular ejection frac-
tion increased from 28 ± 10% to 49 ± 12% with a delta-LVEF ofþ 21 ± 11% in the 1W-group, and from 27 ± 10% to
51 ± 10% with a delta-LVEF ofþ 24 ± 11% in the 8W-group (delta-LVEF: P= 0.381). Full-recovery (LVEF >_ 50%) was
present in 52% of the 1W- and in 68% of the 8W-group with no differences in secondary end points between both groups
(hospitalizations for heart failure: 1W: 9.7% vs. 8W: 6.5%, P= 0.651). The risk within the 8W-group to fail full-recovery
after 6 months tended to be lower. No patient in the study needed heart transplantation, LV assist device or died.
...................................................................................................................................................................................................
Conclusion Bromocriptine treatment was associated with high rate of full LV-recovery and low morbidity and mortality in
PPCM patients compared with other PPCM cohorts not treated with bromocriptine. No significant differences
were observed between 1W and 8W treatment suggesting that 1-week addition of bromocriptine to standard
heart failure treatment is already beneficial with a trend for better full-recovery in the 8W group.
...................................................................................................................................................................................................
Clinical trial
registration:
ClinicalTrials.gov, study number: NCT00998556.
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Introduction
Peripartum cardiomyopathy (PPCM) is increasingly recognized as a
major cause of pregnancy related heart failure with high morbidity and
mortality.1–4 The reported incidence of PPCM is regionally different
ranging between 1 per 100 in Nigeria, 1 in 299 in Haiti to 1 in 1149–
3189 live births in the USA.1,5–7 To date no evidence-based disease
specific therapy is available for PPCM. Recommended treatment for
PPCM is similar to that of heart failure from other aetiologies based on
registry data and expert opinion.2,4,8–10 Although the aetiology of
PPCM is still under investigation, in recent years a number of contribu-
tory mechanisms have been recognized to initiate and propagate the
disease.1–4 Hereby, high levels of the nursing hormone prolactin and
the production of a cleaved 16kDa N-terminal fragment of prolactin
have emerged as potential key factors in the pathophysiology of
PPCM. Experimental studies suggest that 16kDa prolactin induces pro-
found endothelial damage and subsequent cardiomyocyte dysfunction
and full-length prolactin promotes inflammation in PPCM while inhibi-
tion of prolactin release by the dopamine-D2-receptor agonist bro-
mocriptine prevents onset of PPCM.11–14 Bromocriptine has been
used for many years to stop lactation in postpartum women. In addi-
tion, prolactin-independent cytoprotective effects of bromocriptine
were also shown in various organs including the heart.14,15 The strong
improvement of cardiac function in previous reports including a clinical
pilot study and register-based data demonstrating that prolonged
treatment of PPCM patients with bromocriptine is feasible and may
improve left ventricular (LV) recovery and clinical outcome12,16,17 lend
support to the hypothesis that prolonged bromocriptine treatment
beyond the cumulative dose to stop lactation might be needed to
achieve maximum clinical benefits. We therefore designed this
randomized multicentre trial to compare the effects of prolonged bro-
mocriptine treatment vs. short-term treatment sufficient to stop lacta-
tion in addition to guideline-based heart failure therapy9,10 on LV
function and clinical outcomes in patients with PPCM.18
Methods
The study design has been reported previously.18
Detailed information on the study protocol and methods are provided
in the Supplementary material online.
Results
Screening, inclusion criteria, and
randomization of study patients
From June 2010 until September 2015, 140 patients at 12 centres
were screened for eligibility. Of these patients, 63 were included in
the study while 77 patients did not fulfil the criteria for randomiza-
tion. Reasons for exclusion were LVEF > 35%, other reasons for
heart failure, time since delivery more than 6 months, social reasons,
not agreed to participate in the study, drug abuse, incompliance and
other reasons. All patients included in the study were postpartum.
Accordingly, 32 patients were randomly assigned to receive 2.5 mg
bromocriptine for 1 week (1W group) and 31 to receive 5 mg bro-
mocriptine for 2 weeks followed by 2.5 mg for 6 weeks (8W group).
In the 1W group, three patients withdrew consent after randomiza-
tion, one was lost to follow-up, one did not undergo valid randomiza-
tion. An additional patient of the 1W group was not treated
according to the protocol but received higher dose of bromocriptine
(up to 10 mg) and relevantly longer so that the clinical event commit-
tee (CEC) decided to exclude her from all between-groups compari-
sons of efficacy end points. Therefore, 31 patients per group
comprised the efficacy analysis set of patients. In total, 26 patients
from the 1W group and 31 from the 8W group completed the study
with follow-up data of 6 months after diagnosis (Figure 1). Of these
patients, 23 patients from the 1W and 28 patients from the 8W
group met the imaging quality standards evaluated by the CEC in
order to be taken into consideration for the primary end point (trial
profile is shown in Figure 1).
Baseline characteristics of study patients
The characteristics of all randomized patients at baseline (Visit 1) are
shown in Table 1. More details about the baseline characteristics are
Figure 1 Randomization, treatment, and follow-up of the
patients. Left ventricular ejection fraction (LVEF), §patient was
excluded from all between-groups comparisons for efficacy; *23
with adequate imaging quality for primary end point. # 28 with
adequate imaging quality for primary end point. §One patient was
not treated according to protocol and excluded from efficacy
analyses.
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..provided in the Supplementary material online, Appendix Tables S1–S8.
The groups were balanced with respect to baseline characteristics
(age, gravida, parity, race, body mass index, haemodynamics, cardiac
function New York Heart Association class), cardiovascular and
pregnancy-related risk factors. Data for right ventricular ejection frac-
tion (RVEF) as assessed by CMR were available for 44 patients.
Baseline RVEF did not differ significantly between 1W (48 ± 12%,
n= 20) and 8W (42 ± 13%, n= 24; 1W vs. 8W: P= 0.20). The preva-
lence of impaired RV function (RVEF < 40%) did not differ significantly
between both groups (20% in 1W vs. 42% in 8W, P= 0.19) although
patients in the 8W group tended to have more often impaired RV
function at baseline. No patient was diagnosed with PPCM in a
previous pregnancy or was diagnosed during pregnancy. Diagnosis was
made 1.6 ± 1.6 months after delivery and average time between first
symptoms and diagnosis was 0.8 ± 1.2 months with no difference
between groups. All patients were randomized postpartum.
Randomization was done no more than 7 days after first diagnosis of
PPCM. One patient was of African race, all other were of Caucasian
race. Notably, use of guideline-based heart failure therapy including
ACE inhibition or angiotensin receptor blocker (ARB), beta-blockade
and mineralocorticoid receptor antagonist (MRA)9,10 during the study
was high and did not differ between both groups (Table 1). No
patient in the 1W group resumed lactation after bromocriptine
treatment.
....................................................................................................................................................................................................................
Table 1 Baseline characteristics of all randomized patients
Characteristic 1W bromocriptine (N5 32) 8W bromocriptine (N5 31)
Age—year 33.8 ± 5.8 34.0 ± 4.5
Median gravida (range) 1.5 (1–7) 2 (1–5)
Median parity (range) 1.5 (1–7) 2 (1–6)
Race or ethnic group—number (%)a
Caucasian 32 (100) 30 (97)
Black 0 (0) 1 (3)
Systolic blood pressure—mmHg 117 ± 18 111 ± 17
Heart rate—beats per minute 90 ± 16 84 ± 12
Body mass indexb 28.3 ± 6.8 29.0 ± 7.9
Serum creatinine—mg/dL 0.8 ± 0.2 0.9 ± 0.2
Clinical features of heart failure
Left ventricular ejection fraction—(%) 28 ± 10 27 ± 9
Right ventricular ejection fraction—(%)c 48 ± 12 42 ± 13
Median NT-proBNP—pg/mL 2164 (1290–3066) 2437 (1423–4158)
NYHA functional class—number (%)d
I 0 (0) 1 (3.2)
II 4 (12.5) 4 (12.9)
III 10 (31.3) 9 (29.0)
IV 18 (56.3) 17 (54.8)
Medical history—number (%)
Hypertension 7 (21.9) 11 (35.5)
Diabetes 2 (6.3) 1 (3.2)
Smoker or former smoker 16 (50) 15 (48)
Pregnancy related conditions—number (%)
Preeclampsia 5 (15,6) 8 (25.8)
Gestational diabetes 3 (9.4) 2 (6.5)
Treatment at randomization—number (%)
ACE inhibitor 30 (93.8) 27 (87.1)
Angiotensin receptor blocker 3 (9.4) 3 (9.7)
Mineralcorticoid antagonist 27 (84.6) 25 (80.6)
Beta-blocker 29 (90.6) 31 (100)
Diuretic 28 (88.5) 28 (90.3)
Plus–minus values are means ± SD. There were no significant differences between the two groups. Data were missing for the following characteristics: N-terminal pro-B-type
natriuretic peptide for 1 patient in the 1W group and 1 in the 8W group, respectively, body-mass index, for 1 patient in the 1W group. Percentages may not total 100 because
of rounding. To convert the values for creatinine to micromoles per litre, multiply by 88.4.
IQR, interquartile range; NYHA, New York Heart Association.
aRace or ethnic group was reported by the investigators.
bThe body mass index is the weight in kilograms divided by the square of the height in meters.
cThe data for right ventricular ejection fraction were available for n= 44 patients (1W: n= 20; 8W: n= 24).
dThe data for NYHA class reflect the status of patients at the time of randomization.
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Change in left ventricular function as
primary end point
The LVEF increased from a mean of 28 ± 10% at baseline to 49 ± 12%
at 6 months in the 1W group (n= 23), and from 27 ± 10% to
51 ± 10% in the 8W group (n= 28) with a between-groups difference
at 6-months follow-up of 2.0 [95% confidence limit: -4.2; 8.2]% in
favour of the 8W groups. Individual courses are presented in Figure
2A. Delta LVEF was slightly higher in the 8W group (þ24 ± 11%)
compared with the 1W group (þ21 ± 11%) but this was not statisti-
cally significant (P= 0.381) with 2.5 [95% confidence limit: -3.2; 8.3]%.
In order to analyse effects of the two treatment concepts in more
critically ill patients, a subgroup analysis was performed including only
patients in whom baseline LVEF was <30%. As shown in Figure 2B,
the LVEF increased from a mean of 21 ± 6% at baseline to 45 ± 14%
at 6 months in the 1W group (n= 14), and from 21 ± 6% to 50 ± 11%
in the 8W group (n= 18) again showing a slightly higher delta LVEF in
the 8W subgroup (þ29 ± 10%) as compared with delta LVEF of the
1W subgroup (þ24 ± 11%) which was not statistically significant
(8W vs. 1W: P= 0.222). Between-groups differences at 6-months
follow-up of LVEF change of 4.3 [95% confidence limit: -4.6; 13.2]%
and for LVEF change of 4.7 [95% confidence limit: -2.9; 12.4]% in
favour of the 8W groups were observed.
Recovery rate of left ventricular function
in peripartum cardiomyopathy patients
after 6-months follow-up
After 6 months follow-up 52% of the 1W-patients (n= 32) showed
full functional LV recovery (LVEF >_50%), 21% partial recovery (LVEF
between 35% and <50%) and 28% no recovery (LVEF <35%), prema-
turely terminated the trial or had missing LVEF data. In the 8W arm
(n= 31), the respective rates were 68% for full functional recovery,
25% for partial recovery, and 7% for no recovery. Full recovery rates
showed a descriptive benefit for the 8W group (68% compared with
52% in 1W group).
Fisher exact test (two-sided) resulted in P= 0.283 and revealed an
OR= 0.508 [confidence limit: 0.173, 1.490] showing that—although
not significant—the risk within the 8W group to fail ‘full recovery’
after 6 months is reduced.
Change in left ventricular function over
time as assessed by echocardiography
We also analysed LVEF determined by echocardiography, which was
performed immediately after patients’ inclusion (Visit 1) with sequen-
tial performance at 2 weeks (Visit 2), 1 month (Visit 3), 3 months
(Visit 4) and 6 months (Visit 5) after randomization (Figure 3B).
Echocardiographic recordings meeting the quality standards of the
core lab were available from 45 patients displaying a mean baseline
LVEF of 23 ± 7%. There was no difference in baseline LVEF measured
by echocardiography between the 1W (23 ± 7%, n= 21) and the 8W
(23 ± 8%, n= 24) group. After the 6 months follow-up, the absolute
improvement (delta LVEF) in the 1W group wasþ25 ± 12%
andþ27 ± 11% in the 8W group, which was not statistically signifi-
cant (P= 0.581).
Secondary end points of study outcome
Secondary end points were hospitalization for heart failure, cardiac
transplantation, and death of patient during trial, or combinations of
these conditions (Table 2). Among the patients of the 1W group 3 of
31 (=9.7%) and among the patients of the 8W group 2 of 31 (=6.5%)
were hospitalized for heart failure until the end of study (Table 2).
Only one patient was listed for transplantation during the trial but
was removed from the waiting list at follow-up due to improvement
of the clinical condition and cardiac function. None of the patients
received a left ventricular assist device (LVAD) or a heart transplanta-
tion, and no patient died. Altogether, the secondary end points of
clinical events did not significantly differ between treatment groups
(P= 0.651).
Safety of study treatment
A total of six serious adverse events (SAEs) in four patients were
reported, and all SAEs occurred in patients of the 1W group (Table 3).
Therefore, no dose relationship can be concluded from the results.
For three of the SAEs, causality was considered possible with respect
to treatment with bromocriptine. In all three cases, SAE occurred
after termination of bromocriptine therapy. These SAEs included two
venous embolisms and one peripheral artery occlusion. A complete
list of all adverse events (AEs) and adverse reactions is provided in the
Supplementary material online, Appendix Tables S12–S14.
Figure 2 Analyses of global left ventricular ejection fraction
(LVEF) change from baseline to 6 months follow-up determined by
CMR. (A) Individual courses of LVEF change from baseline to 6-
months follow-up in the 1W group (n= 23) and 8W group (n= 28)
with a between-groups difference at 6-months follow-up of 2.0% in
favour of the 8W groups (P= 0.38). (B) Individual courses of LVEF
change from baseline to 6-months follow-up for the subgroup of
patients with LVEF <30% at study entry in the 1 W group (n= 14)
and the 8W group (n= 18) with between-groups differences at 6-
months follow-up of 4.3% and for LVEF change of 4.7% in favour of
the 8W groups (P= 0.22).
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Comparison of outcome with IPAC study
As a limitation of our study, we do not have a placebo control group
because it was considered unethical given the results of previous
registry data and pilot studies12,16,17 and the risk for mastitis for stop-
ping lactation without medical support. We therefore compared a
subgroup of our collective characterized by a baseline LVEF <30%
(echocardiography) with a subgroup of PPCM patients with a base-
line LVEF <30% (echocardiography) from the Investigation in
Pregnancy Associate Cardiomyopathy (IPAC) collective, which has
been analysed over the same time period and obtaining comparable
standard therapy for heart failure but no bromocriptine.19 In the
IPAC subgroup (n= 27 patients), 37% remained in severe heart fail-
ure after a follow-up period of 6–12 months. In addition, the rate of
transplantation and/or use of LVAD was 19%, and the mortality rate
was 15% (Table 4). In the present study, 37 patients (n= 18 in the 1W
and n= 19 in the 8W group) displayed a baseline LVEF <30% with at
least 6-months follow-up. No patient in the 1W or the 8W group
died, needed heart transplantation or a LVAD (Table 4). In the 1W
group two and in the 8W group three patients did not recover LVEF
above 35% after 6 months. Follow-up analyses after >_12 months
were available for these five patients showing that three patients dis-
played complete recovery (LVEF >_50%), and one patient showed
substantial recovery with an LVEF of 47% and only one patient in the
8W group remained in severe heart failure (Table 4). However, this
patient showed poor adherence to standard heart failure medication
during follow-up.
Discussion
Our study is the first prospective, randomized, and multicentre trial
at adequate size to test short- vs. long-term inhibition of prolactin by
bromocriptine as a causal therapy for PPCM. It demonstrates that
inhibition of prolactin release with long-term or short-term bromoc-
riptine in addition to standard therapy for heart failure in patients
with severe forms of PPCM is associated with a high recovery rate
and very low rate of adverse outcome. In fact no patient died or
needed a heart transplantation or a LVAD and full recovery rate was
higher than in any ever published PPCM collective.3,6,16,20–26 In addi-
tion, our study population tolerated bromocriptine well suggesting
that both, short- and long-term application appear to be safe since
attention was paid to ensure sufficient anticoagulant therapy during
treatment. The study did not detect a significant benefit for pro-
longed inhibition of prolactin release with bromocriptine in addition
to standard therapy for heart failure in increasing LVEF or reducing
hospitalization for heart failure compared with short-term
Figure 3 Outcome of patients at 6-months follow-up. (A) Left ventricular ejection fraction (LVEF) at 6-months follow-up according to predefined
categories in all patients of the present study (treated 1W, n= 32 or 8W, n= 31 with bromocriptine, baseline LVEF <35%). Red columns illustrate
the percentage of patients with no recovery (event or final LVEF <35%, prematurely terminated the trial or had missing LVEF data), yellow columns
illustrate the percentage of patients with partial recovery (final LVEF 35% to < 50%) and green columns depict percentage of women with complete
recovery (final LVEF >_50%). (B) Step-wise change in LVEF measured by echocardiography during follow-up period in the 1 W (n= 21) and the 8W
group (n= 24). The number 1–5 marks time course of the five patients who did not recover LVEF >35% after 6-months. However, after >_12 months
Number 1 displayed a LVEF = 62%, 2 a LVEF = 47%, 3 and 4 a LVEF = 50%, and 5 a LVEF = 15%.
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..bromocriptine application sufficient to stop lactation in patients with
PPCM. However, we observed a trend for more patients reaching
full recovery after 6 months in the 8W group suggesting a small bene-
fit of prolonged bromocriptine treatment.
Despite advances in understanding the pathomechanisms of
PPCM, clinical trials testing disease-specific therapeutics beyond
standard therapy for heart failure in this condition are scarce.2,4,8–10
The nursing hormone prolactin and specifically its cleaved 16 kDa
form is considered to play a key role in the pathophysiology of PPCM
(Figure 4).12,13,16,17 However, unlike the placebo controlled study by
Sliwa et al.17 the present study was not designed to compare bro-
mocriptine therapy with placebo but to compare two different dose
regimes of bromocriptine in severely diseased PPCM patients: A
short-term regime that is sufficient to suppress lactation and a long-
term regime that may exert additional cardioprotective effects.
The primary end point of our study, the global improvement in
LVEF at 6 months, was not significantly different among the short-
term and long-term bromocriptine groups, although the long-term
treatment descriptively showed a higher rate of predefined full LV
recovery. It is important to note, that the overall outcome among all
patients enrolled in this study was better than the outcome of any
prospective study on PPCM reported so far: Only 7% of all patients
remaining in the study with complete data sets were still in severe LV
dysfunction (EF <35%) at 6-months follow-up and only 3% remained
....................................................................................................................................................................................................................
Table 2 Effect of treatment on secondary end points
End point 1W bromocriptine (N531)a 8W bromocriptine (N531) P-value
Hospitalization for heart failure 3 (9.7) 2 (6.5) 0.651
Cardiac transplantation 0 (0) 0 (0) n.a.
Death of patient during trial period 0 (0) 0 (0) n.a.
Combination of hospitalization for heart failure, cardiac
transplantation or death
3 (9.7) 2 (6.5) 0.651
Data are numbers of events (%).
aOne patient of the 1W group who was not treated according to the protocol but received higher dose of bromocriptine (up to 10 mg) for a relevantly longer time was
excluded from the endpoint analysis.
Figure 4 Disease specific therapy with bromocritine. Scheme depicting inducers of increased oxidative stress in the peripartum maternal heart
that mediate the generation of antiangiogenic 16kDa prolactin from the nursing hormone prolactin which drives PPCM as well as the hypothetic
mechanisms how the prolactin release blocker bromocriptine together with standard heart failure medication interferes with it.
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..in heart failure thereafter. Moreover, none of the patients experi-
enced a major adverse event including death, cardiac transplantation
or LVAD implantation. It has to be noted that all patients were
randomized no longer than 7 days after first diagnosis in a severe dis-
ease state (LVEF <_35%), thereby no selection for more stable
patients was ensured. In a comparable group of patients in Germany,
we previously reported a 15% treatment failure in a German registry
with prospective data of 96 PPCM patients despite standard heart
failure drug therapy.1,16 Importantly, in the German registry the per-
centage of patients with persistent severe LV dysfunction was signifi-
cantly higher among those patients who did not receive
bromocriptine. The rate of maternal major adverse events among all
patients in the German registry was 10% with a mortality rate of 2%.
Interestingly, in the recent prospective North American IPAC study
including PPCM patients with LVEF < 45% a comparable event rate of
7% and a mortality rate of about 4% were reported.19 In the IPAC
study a subgroup of severely diseased patients with an LVEF <30%
was analysed of whom 37% reached an LVEF >_50% (full recovery)
and an equal number, 37% experienced a major event (transplanta-
tion/LVAD: 19% or death: 15%) or a final LVEF <35%.19 We
identified a similar subgroup in our study that presented with a base-
line LVEF <30%, that however displayed a substantially better out-
come (62% full recovery and 0% LVAD, HTX or death, only 3% with
persistently LVEF <35%). Although this indirect comparison has to
be interpreted with caution given some differences in the population
characteristics, in particular the proportion of patients with African
origin (2% in our study vs. 27% in the IPAC study) for whom progno-
sis might be worse,21 it seems to further support the view that there
is a benefit of bromocriptine treatment. In fact, also in non-African
countries, i.e. for example in Turkey, mortality rates for PPCM
between 25 and 30% were reported.20 In view of these studies, a
treatment concept that combines short-term low dose bromocrip-
tine with standard heart failure therapy, as evaluated in the present
study, appears to be associated with a better outcome, although a
number of factors have to be taken into account which may have an
impact on patient outcome, such as different ethnicities with poten-
tially different genetic dispositions and different medical care
opportunities.
An important reason for the beneficial effect of bromocriptine
treatment may also be the associated ablactation which enables early
....................................................................................................................................................................................................................
Table 4 Effect of treatment on outcome in peripartum cardiomyopathy patients with left ventricular ejection fraction
<30% in the bromocriptine study (treated either with 1W or 8W bromocriptine) compared with the IPAC study without
bromocriptine treatment19
Follow-up
characteristics
1W bromocriptine
baseline LVEF
<30% (n518)
8W bromocriptine
baseline
LVEF <30% (n5 19)
1W and 8W bromocriptine
baseline LVEF
<30% (n5 37)
IPAC study placebo
baseline LVEF
<30% (n527)
LVEF <35% 0% (0/18) 5% (1/19) 3% (1/37) 37%
LVEF 35–49% 22% (6/18) 37% (7/19) 35% (13/37) 26%
Full recovery, LVEF >_50 67% (12/18) 58% (11/19) 62% (23/37) 37%
LVAD and HTX 0% (0/18) 0% (0/19) 0% (0/37) 19% (5/27)
Death 0% (0/18) 0% (0/19) 0% (0/37) 15% (4/27)
LVEF was analysed by echocardiography in the core labs of both studies. Follow-up in the IPAC study was 12 months, follow-up in our study was at 6–36 months.
LVEF, left ventricular ejection fraction; LVAD, left ventricular assist device; HTX, heart transplantation.
....................................................................................................................................................................................................................
Table 3 Incidence of serious adverse events during the study by system organ class
System organ class 1W bromocriptine (N5 32)a Relation to bromocriptine 8W bromocriptine (N531) P-value
Cardiac disorders
Coronary artery occlusionb 1 (3.2) Not related 0(0) 1.000
Musculoskeletal disorders
Chest pain 1 (3.2) Unlikely related 0(0) 1.000
Respiratory disorders
Dyspnoea 1 (3.2) Unlikely related 0(0) 1.000
Vascular disorders
Venous Embolism 2 (6.4) Possibly related 0(0) 0.491
Peripheral artery occlusion 1 (3.2) Possibly related 0(0) 1.000
Data are numbers of events (%).
aThe one patient of the 1W group who was not treated according to the protocol but received higher dose of bromocriptine (up to 10 mg) for a relevantly longer time was
included in the safety analyses.
bOcclusion was due to air embolism as a complication during coronary angiography.
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optimal heart failure treatment with beta-blockade, ACE inhibition,
MRA, and ivabradine.2,8,27 No controlled studies have ever analysed
the potential adverse effects of heart failure medication transferred
to the infant in the breast milk, whereas normal growth percentiles
and no adverse outcome were observed for the infants of PPCM
patients in South Africa who terminated breastfeeding.17 Thus, termi-
nating breastfeeding with bromocriptine appears to be safe for the
child and may enable implementation of early intensive heart failure
therapy at high dosages associated with faster recovery of the mother
enabling her to better care for her newborn.
Some concerns have been raised about a potential risk for cerebral
and cardiovascular complications in patients treated with high doses of
bromocriptine.28,29 However, our observation that no adverse event
associated with bromocriptine occurred during bromocriptine treat-
ment in both groups suggests that bromocriptine (together with antico-
agulant therapy) is safe and potentially effective in PPCM patients
although the optimal dosage and duration of therapy to achieve maxi-
mal cardioprotective effects still remains a matter of investigation.
Future studies should also explore whether extended prophylactic anti-
coagulation beyond the period of bromocriptine treatment is required
in these patients with a considerable risk of thromboembolism.
Recent nation-wide observations and population-based studies
estimated a rise in incidence of PPCM worldwide,5–7 emphasizing
that future research should focus on investigating preventive strat-
egies. Moreover, modern echocardiography and cardiac magnetic
resonance imaging have broadened the phenotypic profile of PPCM
showing for example, that in about one-third of PPCM patients the
right ventricle is affected by the disease with lower likelihood to
recover despite optimal therapy.30 The phenotypic heterogeneity of
this disease with variable outcome may reflect additional contributing
factors such as genetic or (auto-)immune mechanisms31,32 that may
determine the course of disease and the clinical outcome. Thus, the
challenge of future research will be to elaborate specific therapeutic
concepts for patients who are likely to be refractory to current treat-
ment options. Since improvement of LV function was similar
between the two bromocriptine regiments, an outcome study testing
the concept appears worthwhile. Currently, our own experience
suggests that critically ill patients (baseline LVEF <25%, cardiogenic
chock) may profit from a prolonged treatment with a higher initial
dosage of bromocriptine (see Supplementary material online, Figure
S1), a feature that is also supported by the trend for faster full-
recovery in the 8W group. This hypothesis needs to be scrutinized in
a prospective randomized outcome trial.
In conclusion, the findings of our study further support a potential
benefit of bromocriptine in addition to standard heart failure therapy
and best supportive care in PPCM patients (Figure 4). It appears that a
short low dose bromocriptine therapy aiming to stop lactation is suf-
ficient in most forms of PPCM. However, the limited numbers of
patients available in single countries warrant large international pro-
spective registries, i.e. PPCM EORP registry [ESC EURObservational
Research Programme (http://www.eorp.org)], to get further insights
into the efficiency of treatment strategies.
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